A Phase II Randomized Study of Cisplatin-Pemetrexed plus either Enzastaurin or Placebo in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer

Publisher： Karger

E-ISSN： 1423-0232|82|1|25-29

ISSN： 0030-2414

Source： Oncology, Vol.82, Iss.1, 2012-01, pp. : 25-29

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The PARAMOUNT Trial: A Phase III Randomized Study of Maintenance Pemetrexed Versus Placebo Immediately Following Induction First-line Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer

By  

Reviews on Recent Clinical Trials, Vol. 8, Iss. 1, 2013-01 ,pp. : 23-28

Bentham Science Publishers

Access to resources Recommend Favorite

Phase II Randomized Study Comparing the Toxicity Profile of Gemcitabine plus Cisplatin with Gemcitabine plus Oral Etoposide in the Treatment of Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 485-492

Karger

Access to resources Recommend Favorite

An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer

By Nuijten Mark J.C.   Aultman Rick   Carpeño Javier de Castro   Vergnenègre Alain   Chouaid Christos   Walzer Stefan   Siebert Uwe  

Current Medical Research and Opinion, Vol. 27, Iss. 11, 2011-11 ,pp. : 2193-2201

Informa Healthcare

Access to resources Recommend Favorite

Cisplatin-Docetaxel Induction plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer Patients: A Phase II Trial

By  

Oncology, Vol. 83, Iss. 6, 2012-09 ,pp. : 321-328

Karger

Access to resources Recommend Favorite

Randomized phase 2 trial of erlotinib in combination with high‐dose celecoxib or placebo in patients with advanced non‐small cell lung cancer

By  

CANCER, Vol. 121, Iss. 18, 2015-09 ,pp. : 3298-3306

John Wiley & Sons Inc

Access to resources Recommend Favorite